Methods of Cancer Diagnosis, Therapy and Prognosis

1. Front Matter

   Pages i-xxxi

   PDF

2. Gastrointestinal Cancers

   1. Introduction: Gastrointestinal Cancer

      • M. A. Hayat

      Pages 3-12

   2. Metastatic Gastrointestinal Cancer: Safety of Cisplatin Combined with Continuous 5-FU Versus Bolus 5-FU and Leucovorin (Methodology)

      • Jacqueline Duffour, Olivier Bouché, Philippe Rougier, Chantal Milan, Laurent Bedenne, Jean-François Seitz et al.

      Pages 13-21

   3. Gastrointestinal Cancer: Endoscopic Submucosal Dissection (Methodology)

      • Atsushi Imagawa

      Pages 23-28

   4. Gastrointestinal Epithelial Neoplasms: Endoscopic Submucosal Dissection (Methodology)

      • Mitsuhiro Fujishiro

      Pages 29-36

   5. Inoperable Abdomino-Pelvic Tumors: Treatment with Radio-Frequency Ablation and Surgical Debulking

      • Nathan W. Pearlman

      Pages 37-41

   6. Gastrointestinal Neuroendocrine Tumors: Diagnosis Using Gastrin Receptor Scintigraphy

      • Martin Gotthardt, Thomas M. Behr, Martin Béhé

      Pages 43-52

3. Esophageal Cancer

   1. Distal Esophagus: Evaluation with 18F-FDG PET/CT Fusion Imaging

      • Domenico Rubello, Cristina Nanni

      Pages 55-61

   2. Endoscopic Ultrasound and Staging of Esophageal Cancer

      • Kanwar Rupinder S. Gill, Timothy A. Woodward

      Pages 63-75

   3. Esophageal Cancer: Role of RNASEN Protein and microRNA in Prognosis

      • Hideyuki Ishiguro, Yoshiyuki Kuwabara, Nobuyoshi Sugito, Yoshitaka Fujii

      Pages 77-81

   4. Esophageal Cancer: Initial Staging

      • Lana Y. Schumacher, Nicole B. Baril, Sherry M. Wren

      Pages 83-95

4. Gastric Cancer

   1. Automated Disease Classification of Colon and Gastric Histological Samples Based on Digital Microscopy and Advanced Image Analysis

      • Levente Ficsor, Bela Molnar

      Pages 99-111

   2. Early Gastric Cancer: Prediction of Metachronous Recurrence Using Endoscopic Submucosal Dissection (Methodology)

      • Hiroshi Yokozaki, Tadateru Hasuo, Shin-ya Satake, Yasuhiro Omori, Naoko Maeda, Korefumi Nakamura et al.

      Pages 113-120

   3. Helicobacter pylori-Infected Neoplastic Gastric Epithelium: Expression of MUC2 as a Biomarker

      • Halagowder Devaraj, A. Anand Kumar, Niranjali Devaraj

      Pages 121-136

   4. Gastric Cancer: Role of Intestinal Metaplasia by Histochemical Detection Using Biopsy Specimens

      • Akiko Shiotani, Ken Haruma, David Y. Graham

      Pages 137-151

   5. Gastric Cancer: Antitumor Activity of RUNX3

      • Zhihai Peng, Keping Xie

      Pages 153-162

   6. Early Gastric Cancer: Laparoscopic Gastrectomy (Methodology)

      • Seigo Kitano, Kazuhiro Yasuda, Norio Shiraishi

      Pages 163-170

   7. Gastric Cancer: Overexpression of Hypoxia-Inducible Factor 1 as a Prognostic Factor

      • Yoshihiro Kakeji, Eiji Oki, Noriaki Sadanaga, Masaru Morita, Yoshihiko Maehara

      Pages 171-180

5. Pancreatic Cancer

   1. Pancreatic Cancer: Hepatoma-Derived Growth Factor as a Prognostic Factor

      • Yasuhiko Tomita, Hirokazu Uyama, Hideji Nakamura

      Pages 183-189

   2. Pancreatic Cancer: 18F-Fluorodeoxyglucose Positron Emission Tomography as a Prognostic Parameter

      • Tatsuya Higashi

      Pages 191-203

Each year, tens of millions of people are respectively. The following data indicate diagnosed worldwide with cancer, and the burden (seriousness) of gastrointestinal more than half of these patients eventu- cancer, liver cancer, and colorectal cancers ally die from this disease. The severity of globally and in the United States. (Table 1) the burden of cancer becomes really clear Surgical and molecular therapies and pr- by knowing that there were ? 10, 862, 496 nostic markers for gastrointestinal stromal new cancer cases (excluding skin cancer) tumors are discussed in this volume. Role in the world in 2002, and the number of of anticancer drugs and monoclonal an- deaths caused by this disease in the same bodies specific for these tumors are also year was ? 6,723,887 (GLOBOCAN). discussed. Imaging modality assessing the The number of deaths due to cancer in the effect of anticancer imatinib on these tumors United States was estimated to be 559, 650 is included. Diagnostic and prognostic (Am. Cancer Soc. ). Cancer is caused by markers of clinical outcomes using che- both external factors (tobacco, chemicals, therapy and hormone replacement therapy radiation, and infectious organisms) and for gastric adenocarcinoma are detailed. internal factors (inherited mutations, hor- Also, are discussed immunohistochem- mones, immune conditions, and mutations try of esophageal cancer progression, and that occur from metabolism). diagnostic and therapeutic methodologies All cancer types caused by cigarette for biliary tumors.

• PET/CT
• Staging
• TNM staging system
• Tumor
• biopsy
• carcinoma
• classification
• computed tomography (CT)
• diagnosis
• endoscopy
• image analysis
• imaging
• neuroendocrine tumor
• positron emission tomography
• ultrasound
• surgical oncology
• Radiaton Oncology

• Department of Biological Sciences, Kean University, Union, USA

  M. A. Hayat

Policies and ethics